Determining the best window for BNT162b2 mRNA vaccination for SARS-CoV-2 in patients with multiple sclerosis receiving anti-CD20 therapy | Zendy

Audrey Rico | Zendy; Läétitia Ninove | Zendy; Adil Maarouf | Zendy; Clémence Boutière | Zendy; Pierre Durozard | Zendy; Sarah Demortière | Zendy; Paola Mariela Saba Villarroel | Zendy; Abdennour Amroun | Zendy; Toscane Fourié | Zendy; Xavier de Lamballerie | Zendy; Jean Pelletier | Zendy; Bertrand Audoin | Zendy

Open Access

Determining the best window for BNT162b2 mRNA vaccination for SARS-CoV-2 in patients with multiple sclerosis receiving anti-CD20 therapy

Author(s) -

Audrey Rico,

Läétitia Ninove,

Adil Maarouf,

Clémence Boutière,

Pierre Durozard,

Sarah Demortière,

Paola Mariela Saba Villarroel,

Abdennour Amroun,

Toscane Fourié,

Xavier de Lamballerie,

Jean Pelletier,

Bertrand Audoin

Publication year - 2021

Publication title -

multiple sclerosis journal - experimental translational and clinical

Language(s) - English

Resource type - Journals

ISSN - 2055-2173

DOI - 10.1177/20552173211062142

Subject(s) - medicine , vaccination , rituximab , covid-19 , serology , immunology , b cell , antibody , virology , outbreak , disease , infectious disease (medical specialty)

We studied the serologic response to the BNT162b2 mRNA vaccine at four weeks after the second dose in patients with RRMS treated with rituximab with extended-interval dosing ( n = 26). At four weeks, 73% of patients were seropositive. No patient without B cells at the first dose ( n = 4) was seropositive. Four of seven (57%) patients with B-cell proportion >0% and ≤5% were seropositive. All patients with B-cell proportion >5% ( n = 15) were seropositive. In all patients, quantitative ELISA measures after vaccination were correlated with B-cell counts measured before vaccination. In patients receiving rituximab, seropositivity after BNT162b2 mRNA vaccination emerged only after B-cell repopulation.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research